Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Tuula Ahtola-Sätilä"'
Autor:
Mayank Singhal, Elina Turunen, Tuula Ahtola-Sätilä, John Aspegren, J. Raymond Bratty, Rainard Fuhr, Krista Ojala, Bert van Veen, Leena Peltonen
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 177
Particle size reduction leads to an increase in the drug dissolution rate, which in turn can lead to a substantial increase in the bioavailability of a poorly soluble compound. To improve bioavailability, a practically insoluble investigational drug,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e05b82c00232f21796f9d6802132c12c
https://pubmed.ncbi.nlm.nih.gov/35738336
https://pubmed.ncbi.nlm.nih.gov/35738336
Autor:
Aki Laakso, Janne Koskimäki, Outi Simola, Ari-Pekka Forsback, Lasse Saloranta, Janek Frantzén, Tuula Ahtola-Sätilä, Miikka Tarkia
Publikováno v:
BioMed Research International
BioMed Research International, Vol 2015 (2015)
BioMed Research International, Vol 2015 (2015)
Nimodipine is a widely used medication for treating delayed cerebral ischemia (DCI) after subarachnoid hemorrhage. When administrated orally or intravenously, systemic hypotension is an undesirable side effect. Intracranial subarachnoid delivery of n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcab92b682db05b0fe397eaf06212d14
https://doi.org/10.1155/2015/715752
https://doi.org/10.1155/2015/715752
Autor:
Tuula Ahtola-Sätilä, Janne Koskimäki, Miikka Tarkia, Lasse Saloranta, Aki Laakso, Janek Frantzén
Publikováno v:
European journal of drug metabolism and pharmacokinetics. 41(3)
Nimodipine is an L-type calcium channel blocker and is used to treat vasospasm in patients with subarachnoid hemorrhage. Its putative mechanism of action is relaxation of smooth muscle cells in cerebral arteries. In addition, nimodipine may have plei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0173c8782eb507e5a1a12a1fd55d52e
https://pubmed.ncbi.nlm.nih.gov/25652785
https://pubmed.ncbi.nlm.nih.gov/25652785
Autor:
Riku Aantaa, Klaus T. Olkkola, Ruut Laitio, Andrew Wighton, Erkki Kentala, T. Iirola, Chris Garratt, Tuula Ahtola-Sätilä, M Lahtinen
Publikováno v:
Critical Care
The aim of this study was to characterize the pharmaco-kinetics of long dexmedetomidine (dexmed) infusions and assess the dose linearity of high doses.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6438cf6cccc3623f38b29ea9202fb267
https://doi.org/10.1186/cc9773
https://doi.org/10.1186/cc9773
Autor:
Riku Aantaa, Andrew Wighton, Erkki Kentala, Chris Garratt, Klaus T. Olkkola, Ruut Laitio, Tuula Ahtola-Sätilä, Maria Lahtinen, T. Iirola
Publikováno v:
Critical Care
Introduction Only limited information exists on the pharmacokinetics of prolonged (> 24 hours) and high-dose dexmedetomidine infusions in critically ill patients. The aim of this study was to characterize the pharmacokinetics of long dexmedetomidine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9529da9764e04655c085751e6a66d354
https://doi.org/10.1186/cc10518
https://doi.org/10.1186/cc10518
Autor:
Pasi Pohjanjousi, P. Välitalo, Toni Sarapohja, Chris Garratt, Andrew Wighton, Tuula Ahtola-Sätilä
Publikováno v:
Clinical Drug Investigation
Background and Objectives Although the pharmacokinetics of dexmedetomidine in healthy volunteers have been studied, there are limited data about the pharmacokinetics of long-term administration of dexmedetomidine in critically ill patients. Methods T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a741e0dd6a1bd4cd1bfd93842203fda